Publications by authors named "Jacqueline M Kraft"
Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes: The STIC2IT Cluster Randomized Clinical Trial.
JAMA Intern Med
September 2018
Importance: Approximately half of patients with chronic conditions are nonadherent to prescribed medications, and interventions have been only modestly effective.
Objective: To evaluate the effect of a remotely delivered multicomponent behaviorally tailored intervention on adherence to medications for hyperlipidemia, hypertension, and diabetes.
Design, Setting, And Participants: Two-arm pragmatic cluster randomized controlled trial at a multispecialty group practice including participants 18 to 85 years old with suboptimal hyperlipidemia, hypertension, or diabetes disease control, and who were nonadherent to prescribed medications for these conditions.
Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): A cluster-randomized pragmatic trial.
Am Heart J
October 2016
Background: Approximately half of patients with chronic cardiometabolic conditions are nonadherent with their prescribed medications. Interventions to improve adherence have been only modestly effective because they often address single barriers to adherence, intervene at single points in time, or are imprecisely targeted to patients who may not need adherence assistance.
Objective: To evaluate the effect of a multicomponent, behaviorally tailored pharmacist-based intervention to improve adherence to medications for diabetes, hypertension, and hyperlipidemia.
Article Synopsis
- The study aimed to compare the cost-effectiveness of two doses of the drug fulvestrant (250 mg vs. 500 mg) in postmenopausal women with advanced breast cancer after previous treatments.
- A Markov model over 24 months indicated that the 500 mg dose was more effective in improving progression-free survival, with an incremental cost-effectiveness of about US$10,972 per month.
- The findings suggest that the 500 mg dose is cost-effective as long as the willingness to pay threshold is at least US$15,000 per month, yet the 250 mg dose remains a viable alternative.